What is Entellus Medical's stock symbol?
Entellus Medical trades on the NASDAQ under the ticker symbol "ENTL."
Where is Entellus Medical's stock going? Where will Entellus Medical's stock price be in 2017?
6 brokers have issued twelve-month target prices for Entellus Medical's stock. Their forecasts range from $16.00 to $26.00. On average, they expect Entellus Medical's stock price to reach $22.80 in the next twelve months.
When will Entellus Medical announce their earnings?
Entellus Medical is scheduled to release their next quarterly earnings announcement on Tuesday, May, 2nd 2017.
What are analysts saying about Entellus Medical stock?
Here are some recent quotes from research analysts about Entellus Medical stock:
According to Zacks Investment Research, "Entellus Medical, Inc. is a medical technology company. It is engaged in the designing, development and commercialization of products for the treatment of chronic sinusitis. The company operates primarily in the United States and Canada. Entellus Medical, Inc. is headquartered in Plymouth, Minnesota. " (1/31/2017)
Canaccord Genuity analysts commented, "We maintain our BUY rating following marketing meetings with management. We recently hosted Entellus Medical’s management team for a day of investor meetings in Boston. We traveled with Bob White, President and CEO and Brent Moen, CFO. Meetings were largely positive as procedural growth (both office based and OR) and reimbursement changes remain a focus for investors. We came away from those meetings with a clearer understanding of reimbursement changes, broader product portfolio, and OUS growth potential. Net, net we remain positive about Entellus’ growth opportunities despite investor uncertainty on the reimbursement front headed into 2017. Near term, as management noted on the Q3/16 conference call, we expect Entellus will set conservative guidance for 2017 to the low end of the historic 20%-25% range, and as such, set the potential for a beat and raise cadence over the H2/17. We expect reimbursement will be at the forefront of investor minds moving into 2017 as the industry digests 30-50% cuts to reimbursement in the hospital outpatient setting." (12/20/2016)
Who owns Entellus Medical stock?
Entellus Medical's stock is owned by a variety of of institutional and retail investors. Top institutional investors include SV Life Sciences Advisers LLC (18.50%), Discovery Group I LLC (3.95%), FMR LLC (3.74%), First Light Asset Management LLC (2.07%), Cortina Asset Management LLC (1.78%) and Arrowpoint Asset Management LLC (1.66%). Company insiders that own Entellus Medical stock include Brian E Farley, James D Surek, Karen E Peterson, Kevin L Mensink, Life Sciences Fu International, Margaret A Boiano and Timothy B Petrick.
Who sold Entellus Medical stock? Who is selling Entellus Medical stock?
Entellus Medical's stock was sold by a variety of institutional investors in the last quarter, including Cortina Asset Management LLC. Company insiders that have sold Entellus Medical stock in the last year include Brian E Farley, James D Surek, Karen E Peterson, Kevin L Mensink, Life Sciences Fu International, Margaret A Boiano and Timothy B Petrick.
Who bought Entellus Medical stock? Who is buying Entellus Medical stock?
Entellus Medical's stock was bought by a variety of institutional investors in the last quarter, including Arrowpoint Asset Management LLC, Millrace Asset Group Inc., Discovery Group I LLC, Royce & Associates LP, William Blair Investment Management LLC, Kingdon Capital Management L.L.C., Renaissance Technologies LLC and Quinn Opportunity Partners LLC.
How do I buy Entellus Medical stock?
Shares of Entellus Medical can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Entellus Medical stock cost?
One share of Entellus Medical stock can currently be purchased for approximately $13.92.